Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-03-27-Speech-4-012"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20030327.1.4-012"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, Commissioner, ladies and gentlemen, combating poverty in the developing countries is
priority of the European Union’s current policy. HIV/AIDS, malaria and tuberculosis are poverty-related diseases which are rampant in the developing countries. It beggars belief that in some developing countries, for example, there is a shortage of teachers because half of the teaching workforce has AIDS. It is high time that the European Union pays special attention to this problem, and so I join the previous speakers in welcoming the Commission’s initiative to invoke Article 169 of the Treaty in order that the Sixth Framework Programme for Research can be used to develop new clinical interventions to combat HIV/AIDS, malaria and tuberculosis.
By establishing networks and coordinating national and regional research programmes, the EU can make a sizeable contribution towards a more efficient policy on research into the development of methods for combating the three above-mentioned diseases. Involving the developing countries themselves, through the European and Developing Countries Clinical Trials Partnership, enables the work to be much more purposeful and means that the research is brought closer to the people concerned. I think that that last point, in particular, is extremely important.
In his excellent report, the rapporteur also dotted a few more i’s and crossed a few more t’s. I welcome that, but I should like to make a couple of short comments. The research programmes should not just focus on the development of new drugs, but also on the question as to the simplest way to administer those drugs. How often does one hear the complaint that, although patients in remote areas of developing countries can find their way to a health centre, when they get the drugs home, they stop taking the medication as soon as they feel better. This results in the development of resistant forms of the disease, as has happened with malaria. This is clearly counter-productive.
The second point to which I should like to draw attention is the synergy with other European programmes. A large amount of money and high-quality research is required. The Commission’s proposal to set up the Erasmus Mundus programme will shortly be given the support of our Parliament. Students from all over the world will then be invited to come and study in Europe. I should like to ask that students from developing countries, in particular, be given a special chance to take part in this, because the developing countries need highly qualified researchers.
EUR 600 million has been allocated for the present proposal, and another 200 million should be coming from the private sector. By helping the researchers, industry, too, can and must make its own considerable contribution."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples